Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First Horizon To Promote Fortamet, Altroprev With 100-Rep Sales Force

This article was originally published in The Pink Sheet Daily

Executive Summary

Andrx divests extended-release metformin and extended-release lovastatin to First Horizon for upfront payment of $50 mil. First Horizon's promotional efforts will focus on growing Fortamet and stabilizing Altoprev's declining market share.

You may also be interested in...



Zovirax Sales Force To Increase Six Fold Based On Biovail Agreement With Sciele

Promotional deal includes profit-sharing arrangement based on revenue targets for an initial term of five years.

Zovirax Sales Force To Increase Six Fold Based On Biovail Agreement With Sciele

Promotional deal includes profit-sharing arrangement based on revenue targets for an initial term of five years.

Biovail/Depomed’s Glumetza Clears FDA For Type 2 Diabetes

The companies are highlighting potential dosing and tolerability advantages for Glumetza (metformin extended-release) to differentiate the drug in a crowded metformin market. Biovail is in discussions with several potential marketing partners for a U.S. launch of the antidiabetic.

Related Content

Topics

UsernamePublicRestriction

Register

PS061868

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel